Pharma Major Lupin Limited reported its financial performance for the first quarter ending June 30th, 2018. These results were taken on record by the Board of Directors at a meeting held in Mumbai today.
Pharma major Lupin announced that it has received EDQM Attestation of Inspection from EDQM (European Directorate for the Quality of Medicines) for its Mandideep facility. The unit was inspected by EDQM during March 2018. The inspection was focused on the Application for Certificate of Suitability for the dossier of Cefaclor along with facility inspection for Quality Management Systems based on cGMP as laid under European Union rules governing Medicinal products.
Pharma major Lupin announced the launch of its Desoximetasone Topical Spray, 0.25%, having received an approval from the United States Food and Drug Administration (FDA) earlier.